666P Final results of phase I/II study of NUC-7738 as monotherapy and in combination with pembrolizumab: Anti-tumor immune response in PD-1 inhibitor-resistant patientsSarah P. Blagden, David J. Harrison, S.N. Symeonides et al.|Annals of Oncology|2024Cited by 3
Abstract C032: NUC-7738 in combination with pembrolizumab in patients with metastatic melanoma: Phase 2 results from the NuTide:701 studySarah P. Blagden, Elizabeth Ruth Plummer, Alison L. Dickson et al.|Molecular Cancer Therapeutics|2023Cited by 1
Abstract 6222: Exposing the heterogeneity of the lipidome in the TME of cutaneous melanoma following treatment with NUC-7738 in combination with anti-PD-1 therapyAlison L. Dickson, David J. Harrison, In Hwa Um et al.|Cancer Research|2024Cited by 1